Suramin blocked hCAP18/LL-37-induced macrophage recruitment and M2 polarization to enhance the therapeutic efficacy of 1,25(OH)2D3 against hepatocellular carcinoma in vitro and in vivo mouse model. Here, CAMP is linked to hepatocellular carcinoma.